Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Pulse Biosciences, Inc. (PLSE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 58,747 $ 61,139 Prepaid expenses and other current assets 1,211 1,008 Total current assets 59,958 62,147 Property and equipment, net 1,755 1,961 Intangible assets, net 2,218 2,551 Goodwill 2,791 2,791 Right-of-use assets 7,670 8,062 Other assets 365 365 Total assets $ 74,757 $ 77,877 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,794 $ 1,573 Accrued expenses 2,844 2,595 Lease liability, current 975 896 Related party note payable, current — 917 Total current liabilities 5,613 5,981 Lease liability, less current 8,644 9,144 Related party note payable, less current — 65,000 Total liabilities 14,257 80,125 Stockholders..." |
|
| 07/27/2023 |
4
| DUGGAN ROBERT W (10% Owner) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised 1,667 options to buy
@ $5.95, valued at
$9.9k
|
|
| 07/20/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/14/2023 |
4
| UECKER DARRIN (Chief Technology Officer) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 200,000 options to buy
@ $7.08, valued at
$1.4M
|
|
| 07/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/07/2023 |
4
| DUGGAN ROBERT W (10% Owner) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised 65,000 options to buy
@ $2.14, valued at
$139.1k
Exercised 65,467 options to buy
@ $2.14, valued at
$140.1k
Exercised 1,666 options to buy
@ $5.95, valued at
$9.9k
|
|
| 07/06/2023 |
4/A
| UECKER DARRIN (Chief Technology Officer) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised (in-or-at-the-money) 7,365 warrants
@ $2.05, valued at
$15.1k
|
|
| 07/06/2023 |
4/A
| Levinson Mitchell E. (Chief Strategy Officer) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised (in-or-at-the-money) 10,935 warrants
@ $2.05, valued at
$22.4k
Exercised (in-or-at-the-money) 814 warrants
@ $2.05, valued at
$1.7k
Exercised (in-or-at-the-money) 143 warrants
@ $2.05, valued at
$293.2 |
|
| 07/06/2023 |
4/A
| Zanganeh Mahkam (Director) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised (in-or-at-the-money) 86,668 warrants
@ $2.05, valued at
$177.7k
|
|
| 06/16/2023 |
4
| DUGGAN ROBERT W (10% Owner) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Exercised (in-or-at-the-money) 5,683,163 warrants
@ $2.05, valued at
$11.7M
Exercised (in-or-at-the-money) 81,025 warrants
@ $2.05, valued at
$166.1k
|
|
| 06/06/2023 |
4
| DUGGAN ROBERT W (10% Owner) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 20,000 options to buy
@ $5.95, valued at
$119k
Granted 39,731 options to buy
@ $5.95, valued at
$236.4k
|
|
| 06/06/2023 |
4
| Soni Manmeet Singh (Director) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 20,000 options to buy
@ $5.95, valued at
$119k
|
|
| 06/06/2023 |
4
| Spray Shelley D (Director) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 20,000 options to buy
@ $5.95, valued at
$119k
|
|
| 06/06/2023 |
4
| Zanganeh Mahkam (Director) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 20,000 options to buy
@ $5.95, valued at
$119k
Granted 20,168 options to buy
@ $5.95, valued at
$120k
|
|
| 06/06/2023 |
4
| van den Broek Richard (Director) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 20,000 options to buy
@ $5.95, valued at
$119k
Granted 28,487 options to buy
@ $5.95, valued at
$169.5k
|
|
| 05/31/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 54,098 $ 61,139 Prepaid expenses and other current assets 849 1,008 Total current assets 54,947 62,147 Property and equipment, net 1,865 1,961 Intangible assets, net 2,384 2,551 Goodwill 2,791 2,791 Right-of-use assets 7,869 8,062 Other assets 365 365 Total assets $ 70,221 $ 77,877 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,160 $ 1,573 Accrued expenses 3,091 2,595 Deferred revenue 4 — Lease liability, current 935 896 Related party note payable, current 801 917 Total current liabilities 6,991 5,981 Lease liability, less current 8,898 9,144 Related party note payable, current 65,000 65,000 Total liabilities 80,8..." |
|
| 05/10/2023 |
SC 13D/A
| DUGGAN ROBERT W reports a 68.7% stake in Pulse Biosciences, Inc. |
| 05/10/2023 |
4
| DUGGAN ROBERT W (10% Owner) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Bought 10,022,937 shares
@ $6.51, valued at
$65.2M
|
|
| 05/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
4
| Levinson Mitchell E. (Chief Strategy Officer) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 17,700 options to buy
@ $8.02, valued at
$142k
Granted 2,000 options to buy
@ $5.81, valued at
$11.6k
|
|
| 05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu... |
| 05/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/02/2023 |
4
| Danahy Kevin Patrick (CEO) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 500,000 options to buy
@ $6.44, valued at
$3.2M
|
|
| 05/02/2023 |
4
| UECKER DARRIN (Chief Technology Officer) has filed a Form 4 on Pulse Biosciences, Inc.|
Txns:
| Granted 500,000 options to buy
@ $6.44, valued at
$3.2M
|
|
| 05/01/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|
|
|